Pilgrim Partners Asia Pte Ltd Invests $2.49 Million in TransMedics Group, Inc. (NASDAQ:TMDX)

Pilgrim Partners Asia Pte Ltd acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 40,000 shares of the company’s stock, valued at approximately $2,494,000. TransMedics Group makes up 2.2% of Pilgrim Partners Asia Pte Ltd’s holdings, making the stock its 12th biggest holding.

Other large investors also recently added to or reduced their stakes in the company. Clear Creek Financial Management LLC acquired a new stake in shares of TransMedics Group in the fourth quarter worth approximately $352,000. Vaughan Nelson Investment Management L.P. grew its holdings in shares of TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after buying an additional 32,605 shares in the last quarter. Baillie Gifford & Co. grew its holdings in shares of TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after buying an additional 34,947 shares in the last quarter. State of Michigan Retirement System acquired a new stake in shares of TransMedics Group in the fourth quarter valued at about $6,734,000. Finally, Zacks Investment Management purchased a new position in shares of TransMedics Group in the third quarter worth about $1,607,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Trading Down 4.6 %

TMDX opened at $67.67 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a market cap of $2.28 billion, a P/E ratio of 71.99 and a beta of 2.14. The business’s 50-day simple moving average is $70.07 and its 200-day simple moving average is $85.74.

Analyst Ratings Changes

A number of analysts have commented on TMDX shares. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Robert W. Baird reduced their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.